Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

New Epistem chief to start six weeks early

David Budd will now take over on 1 March instead of the middle of April as previously anticipated.
New Epistem chief to start six weeks early
Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C

Epistem Holdings' (LON:EHP) new chief executive is to join six weeks earlier than planned.

David Budd will now take over on 1 March instead of the middle of April as previously anticipated.

Budd has more than 20 years of international commercial and operational experience in diagnostics and medical devices, especially in the molecular field.

He joins from Danaher subsidiary Leica Biosystems where he was last post was general manager of Leica Biosystems Amsterdam.

At Leica Biosystems Newcastle, he had global responsibility for marketing, market research and product launches for diagnostic tests.

Epistem revealed yesterday its genedrive diagnostic test had been cleared for European clinical trials in Hepatitis C (HCV) by the Institut Pasteur in Paris.

Genedrive was launched to test for TB in India last year.

Budd said: “I believe Genedrive is an outstanding molecular diagnostic system with significant near term commercial opportunities in tuberculosis testing and across a wide range of other applications in the future.”

PhilW.jpg
Why Invest In Genedrive PLC? Read More Here

Register here to be notified of future GDR Company articles
View full GDR profile

Genedrive PLC Timeline

Related Articles

757z468_Lab-(1).jpg
April 26 2016
Dr Stewart White, Collagen Solutions chief executive, told investors that the new partnership will expedite the roll-out of its medical grade collagen to customers in China.
Cancer cells
Fri
Proactive takes a closer look at Vaxil, an Israeli bio-tech firm which listed in Toronto earlier this year. For investors, it could be a cheap way of getting into the exciting world of immunotherapy.
Cancer
May 02 2016
As UK biotechs are beating a trail to the US craving greater understanding and higher valuation, Doerfler and his team have opted to go in the opposite direction.

© Proactive Investors 2016

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.